{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:26:42Z","timestamp":1788913602303,"version":"build-2803163510"},"reference-count":344,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Sarcoidosis is a systemic granulomatous inflammatory disease of unknown etiology. It affects the lungs in over 90% of patients yet extra-pulmonary and multi-organ involvement is common. Spontaneous remission of disease occurs commonly, nonetheless, over 50% of patients will require treatment and up to 30% of patients will develop a chronic progressive non-remitting disease with marked pulmonary fibrosis leading to significant morbidity and death. Guidelines outlining an immunosuppressive treatment approach to sarcoidosis were recently published, however, the strength of evidence behind many of the guideline recommended drugs is weak. None of the drugs currently used for the treatment of sarcoidosis have been rigorously studied and prescription of these drugs is often based on off-label\u201d indications informed by experience with other diseases. Indeed, only two medications [prednisone and repository corticotropin (RCI) injection] currently used in the treatment of sarcoidosis are approved by the United States Food and Drug Administration. This situation results in significant reimbursement challenges especially for the more advanced (and often more effective) drugs that are favored for severe and refractory forms of disease causing an over-reliance on corticosteroids known to be associated with significant dose and duration dependent toxicities. This past decade has seen a renewed interest in developing new drugs and exploring novel therapeutic pathways for the treatment of sarcoidosis. Several of these trials are active randomized controlled trials (RCTs) designed to recruit relatively large numbers of patients with a goal to determine the safety, efficacy, and tolerability of these new molecules and therapeutic approaches. While it is an exciting time, it is also necessary to exercise caution. Resources including research dollars and most importantly, patient populations available for trials are limited and thus necessitate that several of the challenges facing drug trials and drug development in sarcoidosis are addressed. This will ensure that currently available resources are judiciously utilized. Our paper reviews the ongoing and anticipated drug trials in sarcoidosis and addresses the challenges facing these and future trials. We also review several recently completed trials and draw lessons that should be applied in future.<\/jats:p>","DOI":"10.3389\/fmed.2022.991783","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T04:56:43Z","timestamp":1665550603000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":44,"title":["Sarcoidosis: Updates on therapeutic drug trials and novel treatment approaches"],"prefix":"10.3389","volume":"9","author":[{"given":"Ogugua Ndili","family":"Obi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley Ann","family":"Saketkoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Baughman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1164\/rccm.202002-0251ST","article-title":"Diagnosis and detection of sarcoidosis. An official American thoracic society clinical practice guideline.","volume":"201","author":"Crouser","year":"2020","journal-title":"Am J Respir Crit Care Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1164\/ajrccm.164.10.2104046","article-title":"Clinical characteristics of patients in a case control study of sarcoidosis.","volume":"164","author":"Baughman","year":"2001","journal-title":"Am J Respir Crit Care Med."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2021.106564","article-title":"The impact of demographic disparities in the presentation of sarcoidosis: a multicenter prospective study.","volume":"187","author":"Zhou","year":"2021","journal-title":"Respir Med."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0145-2019","article-title":"Clinical phenotyping: role in treatment decisions in sarcoidosis.","volume":"29","author":"Baughman","year":"2020","journal-title":"Eur Respir Rev."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis.","volume":"58","author":"Baughman","year":"2021","journal-title":"Eur Respir J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1016\/j.jacc.2020.08.042","article-title":"Challenges in cardiac and pulmonary sarcoidosis: JACC state-of-the-art review.","volume":"76","author":"Trivieri","year":"2020","journal-title":"J Am Coll Cardiol."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0146-2019","article-title":"Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis.","volume":"29","author":"Rahaghi","year":"2020","journal-title":"Eur Respir Rev."},{"key":"B8","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/qjmed\/hcl038","article-title":"Presenting characteristics as predictors of duration of treatment in sarcoidosis.","volume":"99","author":"Baughman","year":"2006","journal-title":"QJM."},{"key":"B9","first-page":"204","article-title":"Two year prognosis of sarcoidosis: the ACCESS experience.","volume":"20","author":"Judson","year":"2003","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.chest.2021.07.2166","article-title":"National temporal trends in hospitalization and inpatient mortality in patients with pulmonary sarcoidosis in the United States Between 2007 and 2018.","volume":"161","author":"Alqalyoobi","year":"2022","journal-title":"Chest."},{"key":"B11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.rmed.2018.11.010","article-title":"Sarcoidosis deaths in the United States: 1999-2016.","volume":"149","author":"Kearney","year":"2019","journal-title":"Respir Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1164\/rccm.201010-1679OC","article-title":"Sarcoidosis-related mortality in the United States from 1988 to 2007.","volume":"183","author":"Swigris","year":"2011","journal-title":"Am J Respir Crit Care Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.chest.2017.07.008","article-title":"Predictors of mortality in pulmonary sarcoidosis.","volume":"153","author":"Kirkil","year":"2018","journal-title":"Chest."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01747-2019","article-title":"Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry.","volume":"55","author":"Shlobin","year":"2020","journal-title":"Eur Respir J."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2020.105997","article-title":"Predictors of mortality in fibrosing pulmonary sarcoidosis.","volume":"169","author":"Jeny","year":"2020","journal-title":"Respir Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1055\/s-0040-1709495","article-title":"Advanced pulmonary sarcoidosis.","volume":"41","author":"Gupta","year":"2020","journal-title":"Semin Respir Crit Care Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1080\/17512433.2018.1486706","article-title":"Treatment of sarcoidosis: grading the evidence.","volume":"11","author":"James","year":"2018","journal-title":"Expert Rev Clin Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1080\/17512433.2021.1878024","article-title":"Biologic and advanced immunomodulating therapeutic options for sarcoidosis: a clinical update.","volume":"14","author":"Obi","year":"2021","journal-title":"Expert Rev Clin Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1183\/09031936.00156314","article-title":"Negative clinical trials in sarcoidosis: failed therapies or flawed study design?","volume":"44","author":"Moller","year":"2014","journal-title":"Eur Respir J."},{"key":"B20","first-page":"119","article-title":"The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States.","volume":"29","author":"Judson","year":"2012","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2018-000394","article-title":"First patient-centred set of outcomes for pulmonary sarcoidosis: a multicentre initiative.","volume":"6","author":"Kampstra","year":"2019","journal-title":"BMJ Open Respir Res."},{"key":"B22","article-title":"Scout \u2013 sarcoidosis outcomes taskforce. A systematic review of outcomes to inform the development of a core outcome set for pulmonary sarcoidosis.","volume":"38","author":"Harman","year":"2021","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"key":"B23","first-page":"834","article-title":"Use of third-line therapies in advanced sarcoidosis.","volume":"38","author":"Lower","year":"2020","journal-title":"Clin Exp Rheumatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ahj.2019.10.003","article-title":"Cardiac sarcoidosis multi-center randomized controlled trial (CHASM CS- RCT).","volume":"220","author":"Birnie","year":"2020","journal-title":"Am Heart J."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-020-01290-9","article-title":"Design of a randomized controlled trial to evaluate effectiveness of methotrexate versus prednisone as first-line treatment for pulmonary sarcoidosis: the PREDMETH study.","volume":"20","author":"Kahlmann","year":"2020","journal-title":"BMC Pulm Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1055\/s-0040-1710080","article-title":"Health-related quality of life in sarcoidosis.","volume":"41","author":"Obi","year":"2020","journal-title":"Semin Respir Crit Care Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/MCP.0000000000000612","article-title":"Advanced sarcoidosis.","volume":"25","author":"Baughman","year":"2019","journal-title":"Curr Opin Pulm Med."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11061089","article-title":"Health-related quality of life (HRQoL) in sarcoidosis: diagnosis, management, and health outcomes.","volume":"11","author":"Saketkoo","year":"2021","journal-title":"Diagnostics."},{"key":"B29","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.rdc.2015.08.012","article-title":"Corticosteroids in sarcoidosis.","volume":"42","author":"Judson","year":"2016","journal-title":"Rheum Dis Clin North Am."},{"key":"B30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.rmed.2017.09.003","article-title":"Toxicity risk from glucocorticoids in sarcoidosis patients.","volume":"132","author":"Khan","year":"2017","journal-title":"Respir Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1136\/ard.2008.092163","article-title":"Dose-related patterns of glucocorticoid-induced side effects.","volume":"68","author":"Huscher","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1136\/thx.51.3.238","article-title":"British thoracic society sarcoidosis study: effects of long term corticosteroid treatment.","volume":"51","author":"Gibson","year":"1996","journal-title":"Thorax."},{"key":"B33","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1183\/23120541.00028-2021","article-title":"Type 2 diabetes risk in sarcoidosis patients untreated and treated with corticosteroids.","volume":"7","author":"Entrop","year":"2021","journal-title":"ERJ Open Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1016\/j.rmed.2017.10.022","article-title":"No evidence found for an association between prednisone dose and FVC change in newly-treated pulmonary sarcoidosis.","author":"Broos","year":"2018","journal-title":"Respir Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.rmed.2015.01.019","article-title":"The effect of corticosteroids on quality of life in a sarcoidosis clinic: the results of a propensity analysis.","volume":"109","author":"Judson","year":"2015","journal-title":"Respir Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ejim.2016.03.027","article-title":"Polymorphic variants of the HSD11B1 gene may be involved in adverse metabolic effects of glucocorticoid replacement therapy in Addison\u2019s disease.","volume":"31","author":"Fichna","year":"2016","journal-title":"Eur J Intern Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/cen.13837","article-title":"Factors impacting on the action of glucocorticoids in patients receiving glucocorticoid therapy.","volume":"90","author":"Dineen","year":"2019","journal-title":"Clin Endocrinol (Oxf)."},{"key":"B38","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1164\/arrd.1973.107.4.609","article-title":"A controlled trial of prednisone treatment of sarcoidosis.","volume":"107","author":"Israel","year":"1973","journal-title":"Am Rev Respir Dis."},{"key":"B39","doi-asserted-by":"publisher","first-page":"207","DOI":"10.7326\/0003-4819-73-2-207","article-title":"Pulmonary sarcoidosis: a prospective evaluation of glucocorticoid therapy.","volume":"73","author":"Young","year":"1970","journal-title":"Ann Intern Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"S421","DOI":"10.1513\/AnnalsATS.201707-564OT","article-title":"Disease burden and variability in sarcoidosis.","author":"Gerke","year":"2017","journal-title":"Ann Am Thorac Soc."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10112366","article-title":"State-level health disparity is associated with sarcoidosis mortality.","volume":"10","author":"Lee","year":"2021","journal-title":"J Clin Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1164\/rccm.201906-1250OC","article-title":"Income and other contributors to poor outcomes in U.S. patients with sarcoidosis.","volume":"201","author":"Harper","year":"2020","journal-title":"Am J Respir Crit Care Med."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1177\/23743735221075556","article-title":"Sarcoidosis illuminations on living during COVID-19: patient experiences of diagnosis, management, and survival before and during the pandemic.","volume":"9","author":"Saketkoo","year":"2022","journal-title":"J Patient Exp."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1513\/AnnalsATS.202011-1467OC","article-title":"Barriers to care among patients with sarcoidosis: a qualitative study.","volume":"18","author":"Harper","year":"2021","journal-title":"Ann Am Thorac Soc."},{"key":"B45","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1097\/MCP.0000000000000704","article-title":"Socioeconomic determinants and disparities in sarcoidosis.","volume":"26","author":"Sharp","year":"2020","journal-title":"Curr Opin Pulm Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1080\/14656566.2016.1258061","article-title":"Sarcoidosis: an update on current pharmacotherapy options and future directions.","volume":"17","author":"Brito-Zeron","year":"2016","journal-title":"Expert Opin Pharmacother."},{"key":"B47","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.rmed.2009.12.009","article-title":"Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study.","volume":"104","author":"Schutt","year":"2010","journal-title":"Respir Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/MCP.0b013e3283642a7a","article-title":"Multinational evidence-based world association of sarcoidosis and other granulomatous disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide.","volume":"19","author":"Cremers","year":"2013","journal-title":"Curr Opin Pulm Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","article-title":"Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement.","volume":"174","author":"Baughman","year":"2006","journal-title":"Am J Respir Crit Care Med."},{"key":"B50","first-page":"201","article-title":"A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis.","volume":"23","author":"Rossman","year":"2006","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"key":"B51","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1159\/000328738","article-title":"Long-term treatment with infliximab in patients with sarcoidosis.","volume":"83","author":"Hostettler","year":"2012","journal-title":"Respiration."},{"key":"B52","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1183\/09031936.00227014","article-title":"Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis.","volume":"46","author":"Vorselaars","year":"2015","journal-title":"Eur Respir J."},{"key":"B53","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S2173-5115(11)70020-3","article-title":"Infliximab for treating sarcoidosis patients, Portuguese experience.","volume":"17","author":"Aguiar","year":"2011","journal-title":"Rev Port Pneumol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1378\/chest.09-2576","article-title":"The CD4+ lymphopenic sarcoidosis phenotype is highly responsive to anti-tumor necrosis factor-{alpha} therapy.","volume":"137","author":"Crouser","year":"2010","journal-title":"Chest."},{"key":"B55","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.rmr.2010.06.011","article-title":"[Infliximab treatment for chronic sarcoidosis\u2013a case series].","volume":"27","author":"Jounieaux","year":"2010","journal-title":"Rev Mal Respir."},{"key":"B56","first-page":"123","article-title":"18F-FDG PET as a predictor of pulmonary function in sarcoidosis.","volume":"28","author":"Keijsers","year":"2011","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"key":"B57","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1136\/ard.2002.004226","article-title":"Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients.","volume":"63","author":"Pritchard","year":"2004","journal-title":"Ann Rheum Dis."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1016\/j.rmed.2006.02.017","article-title":"Effectiveness of infliximab in treating selected patients with sarcoidosis.","volume":"100","author":"Saleh","year":"2006","journal-title":"Respir Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1183\/09031936.00055213","article-title":"Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis.","volume":"43","author":"Vorselaars","year":"2014","journal-title":"Eur Respir J."},{"key":"B60","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.semarthrit.2012.10.008","article-title":"Long term follow-up of infliximab efficacy in pulmonary and extra-pulmonary sarcoidosis refractory to conventional therapy.","volume":"43","author":"Russell","year":"2013","journal-title":"Semin Arthritis Rheum."},{"key":"B61","first-page":"49","article-title":"C-reactive protein predicts response to infliximab in patients with chronic sarcoidosis.","volume":"27","author":"Sweiss","year":"2010","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"key":"B62","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1378\/chest.08-1876","article-title":"Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation.","volume":"136","author":"Baughman","year":"2009","journal-title":"Chest."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1183\/09031936.00051907","article-title":"Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial.","volume":"31","author":"Judson","year":"2008","journal-title":"Eur Respir J."},{"key":"B64","first-page":"91","article-title":"Practical eminence and experience-based recommendations for use of TNF-\u03b1 inhibitors in sarcoidosis.","volume":"31","author":"Drent","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2021.101695","article-title":"Exercise as a multi-modal disease-modifying medicine in systemic sclerosis: an introduction by the global fellowship on rehabilitation and exercise in systemic sclerosis (G-FoRSS).","volume":"35","author":"Pettersson","year":"2021","journal-title":"Best Pract Res Clin Rheumatol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/BOR.0b013e32834f19f5","article-title":"Exercise as a therapeutic modality in patients with idiopathic inflammatory myopathies.","volume":"24","author":"Alexanderson","year":"2012","journal-title":"Curr Opin Rheumatol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1080\/17476348.2016.1227244","article-title":"Physical activity and training in sarcoidosis: review and experience-based recommendations.","volume":"10","author":"Strookappe","year":"2016","journal-title":"Expert Rev Respir Med."},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2021.101707","article-title":"A comprehensive framework for navigating patient care in systemic sclerosis: a global response to the need for improving the practice of diagnostic and preventive strategies in SSc.","volume":"35","author":"Saketkoo","year":"2021","journal-title":"Best Pract Res Clin Rheumatol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s00408-015-9784-9","article-title":"Benefits of physical training in sarcoidosis.","volume":"193","author":"Strookappe","year":"2015","journal-title":"Lung."},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3390\/jpm10030097","article-title":"Benefit of wearing an activity tracker in sarcoidosis.","volume":"10","author":"Drent","year":"2020","journal-title":"J Pers Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1183\/13993003.congress-2015.PA831","article-title":"Benefits of physical training in patients with idiopathic or end-stage sarcoidosis-related pulmonary fibrosis: a pilot study.","volume":"32","author":"Strookappe","year":"2015","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"key":"B72","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4137\/IMI.S12783","article-title":"Shared decision making: a fundamental tenet in a conceptual framework of integrative healthcare delivery.","volume":"8","author":"Brooks","year":"2013","journal-title":"Integr Med Insights."},{"key":"B73","first-page":"109","article-title":"Fostering shared decision making with health informatics interventions based on the boosting framework.","volume":"263","author":"de Vries","year":"2019","journal-title":"Stud Health Technol Inform."},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X211015829","article-title":"Treatment expectations as a possible prognostic factor for DMARD response in rheumatoid arthritis: a prospective cohort study.","volume":"13","author":"Mucke","year":"2021","journal-title":"Ther Adv Musculoskelet Dis."},{"key":"B75","year":"2022","journal-title":"U.S. Agency for Healthcare Research and Quality."},{"key":"B76","year":"2021","journal-title":"NIfHaCE. Shared decision making. NICE guideline [NG197]."},{"key":"B77","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2165\/00003088-200544010-00003","article-title":"Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.","volume":"44","author":"Czock","year":"2005","journal-title":"Clin Pharmacokinet."},{"key":"B78","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41397-018-0047-z","article-title":"Genetic markers in methotrexate treatments.","volume":"18","author":"Giletti","year":"2018","journal-title":"Pharmacogenomics J."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1378\/chest.115.4.1158","article-title":"An approach to the treatment of pulmonary sarcoidosis with corticosteroids: the six phases of treatment.","volume":"115","author":"Judson","year":"1999","journal-title":"Chest."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1080\/07853890.2022.2063375","article-title":"Comorbidities of sarcoidosis.","volume":"54","author":"Tana","year":"2022","journal-title":"Ann Med."},{"key":"B81","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1097\/MCP.0000000000000082","article-title":"Worsening of pulmonary sarcoidosis.","volume":"20","author":"Judson","year":"2014","journal-title":"Curr Opin Pulm Med."},{"key":"B82","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S2213-2600(21)00311-8","article-title":"Misconceptions regarding symptoms of sarcoidosis.","volume":"9","author":"Drent","year":"2021","journal-title":"Lancet Respir Med."},{"key":"B83","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.ccm.2015.08.013","article-title":"Consequences of sarcoidosis.","volume":"36","author":"Drent","year":"2015","journal-title":"Clin Chest Med."},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9020390","article-title":"Comprehensive care for patients with sarcoidosis.","volume":"9","author":"Moor","year":"2020","journal-title":"J Clin Med."},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58060768","article-title":"The relationship between tumor development and sarcoidosis in aspects of carcinogenesis before and after the onset of sarcoidosis.","volume":"58","author":"Hachisu","year":"2022","journal-title":"Medicina."},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.21169","article-title":"The association of lung cancer and sarcoidosis: a systematic review.","volume":"14","author":"Srinivasan","year":"2022","journal-title":"Cureus."},{"key":"B87","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3899\/jrheum.210588","article-title":"Risk of cancer among sarcoidosis patients with biopsy-verified nonnecrotizing granulomatous inflammation: population-based cohort study.","volume":"49","author":"Faurschou","year":"2022","journal-title":"J Rheumatol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.hrtlng.2020.03.013","article-title":"Association between sarcoidosis and cardiovascular comorbidity: a systematic review and meta-analysis.","volume":"49","author":"Mahmoud","year":"2020","journal-title":"Heart Lung."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S0761-8425(04)71582-X","article-title":"[Opportunistic infections and sarcoidosis].","author":"Girard","year":"2004","journal-title":"Rev Mal Respir."},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00767-2020","article-title":"Risk of first and recurrent serious infection in sarcoidosis: a Swedish register-based cohort study.","volume":"56","author":"Rossides","year":"2020","journal-title":"Eur Respir J."},{"key":"B91","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s00408-019-00210-x","article-title":"Inpatient prevalence, expenditures, and comorbidities of sarcoidosis: nationwide inpatient sample 2013-2014.","volume":"197","author":"Ungprasert","year":"2019","journal-title":"Lung."},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01290-2016","article-title":"Risk of cardiovascular disease among patients with sarcoidosis: a population-based retrospective cohort study, 1976-2013.","volume":"49","author":"Ungprasert","year":"2017","journal-title":"Eur Respir J."},{"key":"B93","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1513\/AnnalsATS.201610-750OC","article-title":"Sarcoidosis increases risk of hospitalized infection. A population-based study, 1976-2013.","volume":"14","author":"Ungprasert","year":"2017","journal-title":"Ann Am Thorac Soc."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1378\/chest.11-0324","article-title":"Increased risk of pulmonary embolism among US decedents with sarcoidosis from 1988 to 2007.","volume":"140","author":"Swigris","year":"2011","journal-title":"Chest."},{"key":"B95","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1378\/chest.11-2514","article-title":"Increased number of pulmonary embolisms in sarcoidosis patients.","volume":"141","author":"Vorselaars","year":"2012","journal-title":"Chest."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1056\/NEJMra2101555","article-title":"Challenges of sarcoidosis and its management.","volume":"385","author":"Drent","year":"2021","journal-title":"N Engl J Med."},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-021-00870-y","article-title":"The usefulness of repeated CMR and FDG PET\/CT in the diagnosis of patients with initial possible cardiac sarcoidosis.","volume":"11","author":"Mathijssen","year":"2021","journal-title":"EJNMMI Res."},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9030890","article-title":"In which patients with sarcoidosis is FDG PET\/CT indicated?","volume":"9","author":"Keijsers","year":"2020","journal-title":"J Clin Med."},{"key":"B99","first-page":"44","article-title":"Volumetric FDG PET analysis of global lung inflammation: new tool for precision medicine in pulmonary sarcoidosis?","volume":"35","author":"Adams","year":"2018","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"key":"B100","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1093\/ehjci\/jex340","article-title":"Diagnostic accuracy and prognostic value of simultaneous hybrid 18F-fluorodeoxyglucose positron emission tomography\/magnetic resonance imaging in cardiac sarcoidosis.","volume":"19","author":"Wicks","year":"2018","journal-title":"Eur Heart J Cardiovasc Imaging."},{"key":"B101","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.ccm.2015.08.007","article-title":"Neurosarcoidosis.","volume":"36","author":"Tavee","year":"2015","journal-title":"Clin Chest Med."},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci9100243","article-title":"Value of multimodal imaging approach to diagnosis of neurosarcoidosis.","volume":"9","author":"Sammarra","year":"2019","journal-title":"Brain Sci."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1513\/AnnalsATS.201511-760OC","article-title":"Sarcoidosis in America. Analysis based on health care use.","volume":"13","author":"Baughman","year":"2016","journal-title":"Ann Am Thorac Soc."},{"key":"B104","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1183\/09031936.01.00056201","article-title":"Sarcoidosis severity and socioeconomic status.","volume":"18","author":"Rabin","year":"2001","journal-title":"Eur Respir J."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1183\/09031936.00000914","article-title":"Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis.","volume":"44","author":"Judson","year":"2014","journal-title":"Eur Respir J."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1016\/j.chest.2020.12.027","article-title":"Phase II investigation of the efficacy of antimycobacterial therapy in chronic pulmonary sarcoidosis.","volume":"159","author":"Drake","year":"2021","journal-title":"Chest."},{"key":"B107","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1177\/1740774512458992","article-title":"Barriers to therapeutic clinical trials enrollment: differences between African-American and white cancer patients identified at the time of eligibility assessment.","volume":"9","author":"Penberthy","year":"2012","journal-title":"Clin Trials."},{"key":"B108","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.cpcardiol.2018.11.002","article-title":"Increasing diversity in clinical trials: overcoming critical barriers.","volume":"44","author":"Clark","year":"2019","journal-title":"Curr Probl Cardiol."},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2021.1307","article-title":"African American participation in cancer clinical trials.","volume":"15","author":"Swaby","year":"2021","journal-title":"Ecancermedicalscience."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1002\/cncr.11213","article-title":"Barriers to the participation of African-American patients with cancer in clinical trials: a pilot study.","volume":"97","author":"Advani","year":"2003","journal-title":"Cancer."},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06144-9","article-title":"Success and failure factors of patient recruitment for industry-sponsored clinical trials and the role of the electronic health records-a qualitative interview study in the Nordic countries.","volume":"23","author":"Laaksonen","year":"2022","journal-title":"Trials."},{"key":"B112","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.pec.2014.10.018","article-title":"Outcomes from the body & soul clinical trials project: a university-church partnership to improve African American enrollment in a clinical trial registry.","volume":"98","author":"Langford","year":"2015","journal-title":"Patient Educ Couns."},{"key":"B113","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1164\/rccm.202105-1193ST","article-title":"Patient-centered outcomes research in interstitial lung disease: an official American thoracic society research statement.","volume":"204","author":"Aronson","year":"2021","journal-title":"Am J Respir Crit Care Med."},{"key":"B114","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1001\/jamadermatol.2013.60","article-title":"Reliability and convergent validity of the cutaneous sarcoidosis activity and morphology instrument for assessing cutaneous sarcoidosis.","volume":"149","author":"Rosenbach","year":"2013","journal-title":"JAMA Dermatol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2165\/00128071-200809030-00003","article-title":"Chronic facial sarcoidosis including lupus pernio: clinical description and proposed scoring systems.","volume":"9","author":"Baughman","year":"2008","journal-title":"Am J Clin Dermatol."},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01443","article-title":"Biomarkers in the diagnosis and prognosis of sarcoidosis: current use and future prospects.","volume":"11","author":"Kraaijvanger","year":"2020","journal-title":"Front Immunol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1080\/1744666X.2019.1568240","article-title":"Clinically-useful serum biomarkers for diagnosis and prognosis of sarcoidosis.","volume":"15","author":"Ramos-Casals","year":"2019","journal-title":"Expert Rev Clin Immunol."},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00050-2018","article-title":"It\u2019s time to evolve from Scadding: phenotyping sarcoidosis.","volume":"51","author":"Culver","year":"2018","journal-title":"Eur Respir J."},{"key":"B119","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1055\/s-0040-1712534","article-title":"Radiographic and histopathologic features in sarcoidosis: a pictorial display.","volume":"41","author":"Shaikh","year":"2020","journal-title":"Semin Respir Crit Care Med."},{"key":"B120","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1378\/chest.12-2479","article-title":"Accuracy of individual variables in the monitoring of long-term change in pulmonary sarcoidosis as judged by serial high-resolution CT scan data.","volume":"145","author":"Zappala","year":"2014","journal-title":"Chest."},{"key":"B121","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1055\/s-0034-1376866","article-title":"FDG PET for gauging of sarcoid disease activity.","volume":"35","author":"Adams","year":"2014","journal-title":"Semin Respir Crit Care Med."},{"key":"B122","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1378\/chest.07-1178","article-title":"Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis.","volume":"132","author":"Teirstein","year":"2007","journal-title":"Chest."},{"key":"B123","first-page":"26","article-title":"A web-based registry for patients with sarcoidosis.","volume":"34","author":"Gerke","year":"2017","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2021.106436","article-title":"Assessment of dyspnea in sarcoidosis using the baseline dyspnea index (BDI) and the transition dyspnea index (TDI).","volume":"191","author":"Obi","year":"2022","journal-title":"Respir Med."},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2022.106801","article-title":"The six-minute walk test in sarcoidosis associated pulmonary hypertension: results from an international registry.","volume":"196","author":"Gupta","year":"2022","journal-title":"Respir Med."},{"key":"B126","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s00408-017-9994-4","article-title":"Repository corticotropin for chronic pulmonary sarcoidosis.","volume":"195","author":"Baughman","year":"2017","journal-title":"Lung."},{"key":"B127","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1016\/j.chest.2020.04.074","article-title":"Mixed ventilatory defects in pulmonary sarcoidosis: prevalence and clinical features.","volume":"158","author":"Kouranos","year":"2020","journal-title":"Chest."},{"key":"B128","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00408-021-00436-8","article-title":"Tofacitinib as a steroid-sparing therapy in pulmonary sarcoidosis, an open-label prospective proof-of-concept study.","volume":"199","author":"Friedman","year":"2021","journal-title":"Lung."},{"key":"B129","article-title":"Roflumilast (Daliresp(R)) to reduce acute pulmonary events in fibrotic sarcoidosis: a multi-center, double blind, placebo controlled, randomized clinical trial.","volume":"38","author":"Baughman","year":"2021","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"key":"B130","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.chest.2021.07.2162","article-title":"Riociguat for sarcoidosis-associated pulmonary hypertension: results of a 1-year double-blind, placebo-controlled trial.","volume":"161","author":"Baughman","year":"2021","journal-title":"Chest."},{"key":"B131","article-title":"Value of pulmonary function testing identifying progressive pulmonary disease in fibrotic sarcoidosis: results of a prospective feasibility study.","volume":"39","author":"Baughman","year":"2022","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm-conference.2022.205.1_MeetingAbstracts.A3932","article-title":"Safety and efficacy of ATYR1923, a novel immunomodulator for pulmonary sarcoidosis: results of a phase 1b\/2a randomized placebo- controlled trial.","volume":"205","author":"Sporn","year":"2022","journal-title":"Am J Respir Crit Care Med."},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1177\/1753466619888127","article-title":"Repository corticotropin injection in patients with advanced symptomatic sarcoidosis: retrospective analysis of medical records.","volume":"13","author":"Chopra","year":"2019","journal-title":"Ther Adv Respir Dis."},{"key":"B134","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.cardfail.2019.02.018","article-title":"Serial cardiac FDG-PET for the diagnosis and therapeutic guidance of patients with cardiac sarcoidosis.","volume":"25","author":"Ning","year":"2019","journal-title":"J Card Fail."},{"key":"B135","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s12350-021-02567-0","article-title":"Prognosis and recurrence in cardiac sarcoidosis: serial assessment of BMIPP SPECT and FDG-PET.","volume":"28","author":"Yamamoto","year":"2021","journal-title":"J Nucl Cardiol."},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-019-0505-x","article-title":"Quantification of pulmonary disease activity in sarcoidosis measured with (18)F-FDG PET\/CT: SUVmax versus total lung glycolysis.","volume":"9","author":"Schimmelpennink","year":"2019","journal-title":"EJNMMI Res."},{"key":"B137","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/j.1440-1843.2011.01966.x","article-title":"Prognostic value of dual-time-point 18F-fluorodeoxyglucose positron emission tomography in patients with pulmonary sarcoidosis.","volume":"16","author":"Umeda","year":"2011","journal-title":"Respirology."},{"key":"B138","first-page":"143","article-title":"18F-FDG PET in sarcoidosis: an observational study in 12 patients treated with infliximab.","volume":"25","author":"Keijsers","year":"2008","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"key":"B139","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s43441-022-00420-1","article-title":"Design and analysis of studies based on hierarchical composite endpoints: insights from the DARE-19 trial.","volume":"56","author":"Gasparyan","year":"2022","journal-title":"Ther Innov Regul Sci."},{"key":"B140","doi-asserted-by":"publisher","first-page":"106","DOI":"10.4244\/EIJ-D-16-00745","article-title":"Hierarchical testing of composite endpoints: applying the win ratio to percutaneous coronary intervention versus coronary artery bypass grafting in the SYNTAX trial.","volume":"13","author":"Milojevic","year":"2017","journal-title":"EuroIntervention."},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1017\/cts.2021.816","article-title":"Fair payment and just benefits to enhance diversity in clinical research.","volume":"5","author":"Bierer","year":"2021","journal-title":"J Clin Transl Sci."},{"key":"B142","first-page":"61","article-title":"Paying research participants: regulatory uncertainty, conceptual confusion, and a path forward.","volume":"17","author":"Largent","year":"2017","journal-title":"Yale J Health Policy Law Ethics."},{"key":"B143","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/j.rmed.2018.09.016","article-title":"Work ability before and after sarcoidosis diagnosis in Sweden.","author":"Arkema","year":"2018","journal-title":"Respir Med."},{"key":"B144","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s00408-019-00234-3","article-title":"Sarcoidosis and work participation: the need to develop a disease-specific core set for assessment of work ability.","volume":"97","author":"Hendriks","year":"2019","journal-title":"Lung."},{"key":"B145","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1586\/14737167.2015.1065733","article-title":"The indirect costs of systemic autoimmune diseases, systemic lupus erythematosus, systemic sclerosis and sarcoidosis: a summary of 2012 real-life data from the social insurance institution in Poland.","volume":"15","author":"Kawalec","year":"2015","journal-title":"Expert Rev Pharmacoecon Outcomes Res."},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcpo.2021.100305","article-title":"Accelerating cancer clinical trial recruitment through a financial reimbursement program integrated with patient navigation: an interrupted time series analysis.","volume":"30","author":"Borno","year":"2021","journal-title":"J Cancer Policy."},{"key":"B147","first-page":"1","article-title":"Paying research participants: the outsized influence of \u201cundue influence\u201d.","volume":"39","author":"Largent","year":"2017","journal-title":"IRB."},{"key":"B148","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1177\/1740774520905596","article-title":"Economic vulnerability and payment for research participation.","volume":"17","author":"Gelinas","year":"2020","journal-title":"Clin Trials."},{"key":"B149","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/15265161.2020.1854368","article-title":"Promoting ethical payment in human infection challenge studies.","volume":"21","author":"Lynch","year":"2021","journal-title":"Am J Bioeth."},{"key":"B150","doi-asserted-by":"publisher","first-page":"i47","DOI":"10.1093\/rheumatology\/kez338","article-title":"Conducting research in psoriatic arthritis: the emerging role of patient research partners.","author":"Goel","year":"2020","journal-title":"Rheumatology (Oxford)."},{"key":"B151","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/j.1369-7625.2011.00661.x","article-title":"Collaboration and co-ownership in research: dynamics and dialogues between patient research partners and professional researchers in a research team.","volume":"15","author":"Nierse","year":"2012","journal-title":"Health Expect."},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-002241","article-title":"Involving patient research partners has a significant impact on outcomes research: a responsive evaluation of the international OMERACT conferences.","volume":"3","author":"de Wit","year":"2013","journal-title":"BMJ Open."},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1186\/s40900-020-00213-6","article-title":"Guidance on authorship with and acknowledgement of patient partners in patient-oriented research.","volume":"6","author":"Richards","year":"2020","journal-title":"Res Involv Engagem."},{"key":"B154","doi-asserted-by":"publisher","first-page":"413","DOI":"10.2519\/jospt.2020.0106","article-title":"Patients as partners in research: how to talk about compensation with patient partners.","volume":"50","author":"Richards","year":"2020","journal-title":"J Orthop Sports Phys Ther."},{"key":"B155","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1053\/j.semdp.2018.09.001","article-title":"Reprint of: the pathology of pulmonary sarcoidosis: update.","volume":"35","author":"Ma","year":"2018","journal-title":"Semin Diagn Pathol."},{"key":"B156","doi-asserted-by":"publisher","first-page":"S429","DOI":"10.1513\/AnnalsATS.201707-565OT","article-title":"Genetic, immunologic, and environmental basis of sarcoidosis.","volume":"14","author":"Moller","year":"2017","journal-title":"Ann Am Thorac Soc."},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00437","article-title":"Granuloma formation in pulmonary sarcoidosis.","volume":"4","author":"Broos","year":"2013","journal-title":"Front Immunol."},{"key":"B158","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ccm.2008.03.014","article-title":"The immunology of sarcoidosis.","volume":"29","author":"Gerke","year":"2008","journal-title":"Clin Chest Med."},{"key":"B159","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1001\/jama.2011.10","article-title":"Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics.","volume":"305","author":"Iannuzzi","year":"2011","journal-title":"JAMA."},{"key":"B160","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1136\/thx.2010.140319","article-title":"Sarcoidosis is a Th1\/Th17 multisystem disorder.","volume":"66","author":"Facco","year":"2011","journal-title":"Thorax."},{"key":"B161","first-page":"56","article-title":"Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG task force.","volume":"28","author":"Baughman","year":"2011","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"key":"B162","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/00005792-199903000-00001","article-title":"The clinical management of sarcoidosis. A 50-year experience at the Johns Hopkins hospital.","volume":"78","author":"Johns","year":"1999","journal-title":"Medicine (Baltimore)."},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.537382","article-title":"Sarcoidosis epidemiology: race matters.","volume":"11","author":"Hena","year":"2020","journal-title":"Front Immunol."},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0096-x","article-title":"Sarcoidosis.","volume":"5","author":"Grunewald","year":"2019","journal-title":"Nat Rev Dis Primers."},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01340","article-title":"Environmental risk factors for sarcoidosis.","volume":"11","author":"Judson","year":"2020","journal-title":"Front Immunol."},{"key":"B166","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/resp.13482","article-title":"Bidirectional association between tuberculosis and sarcoidosis.","volume":"24","author":"Wang","year":"2019","journal-title":"Respirology."},{"key":"B167","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1111\/1346-8138.15042","article-title":"Identification of Mycobacterium tuberculosis and non-tuberculous mycobacteria from cutaneous sarcoidosis lesions by reverse blot hybridization assay.","volume":"46","author":"Lee","year":"2019","journal-title":"J Dermatol."},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2020.106161","article-title":"Current perspectives on the immunopathogenesis of sarcoidosis.","volume":"173","author":"Lee","year":"2020","journal-title":"Respir Med."},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0192408","article-title":"Propionibacterium acnes-derived insoluble immune complexes in sinus macrophages of lymph nodes affected by sarcoidosis.","volume":"13","author":"Suzuki","year":"2018","journal-title":"PLoS One."},{"key":"B170","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s12026-019-09077-9","article-title":"Catalase expression of Propionibacterium acnes may contribute to intracellular persistence of the bacterium in sinus macrophages of lymph nodes affected by sarcoidosis.","volume":"67","author":"Yamamoto","year":"2019","journal-title":"Immunol Res."},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/935289","article-title":"Etiologic aspect of sarcoidosis as an allergic endogenous infection caused by Propionibacterium acnes.","volume":"2013","author":"Eishi","year":"2013","journal-title":"Biomed Res Int."},{"key":"B172","doi-asserted-by":"publisher","first-page":"8784","DOI":"10.4049\/jimmunol.181.12.8784","article-title":"T cell responses to mycobacterial catalase-peroxidase profile a pathogenic antigen in systemic sarcoidosis.","volume":"181","author":"Chen","year":"2008","journal-title":"J Immunol."},{"key":"B173","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.1128\/IAI.00142-09","article-title":"Cellular responses to mycobacterial antigens are present in bronchoalveolar lavage fluid used in the diagnosis of sarcoidosis.","volume":"77","author":"Oswald-Richter","year":"2009","journal-title":"Infect Immun."},{"key":"B174","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s10875-009-9311-y","article-title":"Mycobacterial ESAT-6 and katG are recognized by sarcoidosis CD4+ T cells when presented by the American sarcoidosis susceptibility allele, DRB1*1101.","volume":"30","author":"Oswald-Richter","year":"2010","journal-title":"J Clin Immunol."},{"key":"B175","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s10875-012-9700-5","article-title":"Dual analysis for mycobacteria and propionibacteria in sarcoidosis BAL.","volume":"32","author":"Oswald-Richter","year":"2012","journal-title":"J Clin Immunol."},{"key":"B176","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrrheum.2011.93","article-title":"Sarcoidosis\u2013scientific progress and clinical challenges.","volume":"7","author":"Chen","year":"2011","journal-title":"Nat Rev Rheumatol."},{"key":"B177","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1097\/MCP.0b013e3283560809","article-title":"Sarcoidosis and tuberculosis: the same disease with different manifestations or similar manifestations of different disorders.","volume":"18","author":"Gupta","year":"2012","journal-title":"Curr Opin Pulm Med."},{"key":"B178","first-page":"25","article-title":"Prolonged culture for mycobacteria in mediastinal lymph nodes from patients with pulmonary sarcoidosis. A negative study.","volume":"21","author":"Milman","year":"2004","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"key":"B179","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1378\/chest.123.2.413","article-title":"Recovery of cell wall-deficient organisms from blood does not distinguish between patients with sarcoidosis and control subjects.","volume":"123","author":"Brown","year":"2003","journal-title":"Chest."},{"key":"B180","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1111\/all.13788","article-title":"Innate immunity in allergy.","volume":"74","author":"Maeda","year":"2019","journal-title":"Allergy."},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01450-2019","article-title":"Subpopulations of cells from bronchoalveolar lavage can predict prognosis in sarcoidosis.","volume":"55","author":"Darlington","year":"2020","journal-title":"Eur Respir J."},{"key":"B182","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.4049\/jimmunol.156.12.4952","article-title":"Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis.","volume":"156","author":"Moller","year":"1996","journal-title":"J Immunol."},{"key":"B183","doi-asserted-by":"publisher","first-page":"642","DOI":"10.4049\/jimmunol.166.1.642","article-title":"IL-12 and IL-18 are increased and stimulate IFN-gamma production in sarcoid lungs.","volume":"166","author":"Shigehara","year":"2001","journal-title":"J Immunol."},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21197398","article-title":"Key players and biomarkers of the adaptive immune system in the pathogenesis of sarcoidosis.","volume":"21","author":"Zhou","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02695-2020","article-title":"Phagosome-regulated mTOR signalling during sarcoidosis granuloma biogenesis.","volume":"57","author":"Crouser","year":"2020","journal-title":"Eur Respir J."},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-04109-6","article-title":"Identification of Jak-STAT signaling involvement in sarcoidosis severity via a novel microRNA-regulated peripheral blood mononuclear cell gene signature.","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci Rep."},{"key":"B187","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.immuni.2006.01.001","article-title":"TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells.","volume":"24","author":"Veldhoen","year":"2006","journal-title":"Immunity."},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01124-2017","article-title":"Increased T-helper 17.1 cells in sarcoidosis mediastinal lymph nodes.","volume":"51","author":"Broos","year":"2018","journal-title":"Eur Respir J."},{"key":"B189","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1164\/rccm.201507-1499OC","article-title":"IFN-gamma-producing T-helper 17.1 cells are increased in sarcoidosis and are more prevalent than T-helper type 1 cells.","volume":"193","author":"Ramstein","year":"2016","journal-title":"Am J Respir Crit Care Med."},{"key":"B190","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.cell.2006.07.035","article-title":"The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells.","volume":"126","author":"Ivanov","year":"2006","journal-title":"Cell."},{"key":"B191","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature."},{"key":"B192","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.smim.2007.10.007","article-title":"Th17 cells: effector T cells with inflammatory properties.","volume":"19","author":"Korn","year":"2007","journal-title":"Semin Immunol."},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20143394","article-title":"Th17 cells and the IL-23\/IL-17 axis in the pathogenesis of periodontitis and immune-mediated inflammatory diseases.","volume":"20","author":"Bunte","year":"2019","journal-title":"Int J Mol Sci."},{"key":"B194","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1440-1843.1998.tb00130.x","article-title":"Secretion of GM-CSF by inflammatory cells in the lung of patients with sarcoidosis.","volume":"3","author":"Itoh","year":"1998","journal-title":"Respirology."},{"key":"B195","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1136\/thx.48.12.1230","article-title":"Correlation of GM-CSF mRNA in bronchoalveolar fluid with indices of clinical activity in sarcoidosis.","volume":"48","author":"Itoh","year":"1993","journal-title":"Thorax."},{"key":"B196","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1159\/000236532","article-title":"Effect of GM-CSF on TNF-alpha and IL-1-beta production by alveolar macrophages and peripheral blood monocytes from patients with sarcoidosis.","volume":"102","author":"Terao","year":"1993","journal-title":"Int Arch Allergy Immunol."},{"key":"B197","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jaut.2017.12.012","article-title":"Th17-lineage cells in pulmonary sarcoidosis and L\u00f6fgren\u2019s syndrome: friend or foe?","volume":"87","author":"Miedema","year":"2018","journal-title":"J Autoimmun."},{"key":"B198","year":"2022","journal-title":"A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis (RESOLVE-Lung)."},{"key":"B199","year":"2022","journal-title":"A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis (RESOLVE-Heart)."},{"key":"B200","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/MCP.0000000000000301","article-title":"From granuloma to fibrosis: sarcoidosis associated pulmonary fibrosis.","volume":"22","author":"Bonham","year":"2016","journal-title":"Curr Opin Pulm Med."},{"key":"B201","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1080\/1744666X.2016.1175301","article-title":"Biologic therapies in the treatment of sarcoidosis.","volume":"12","author":"Saketkoo","year":"2016","journal-title":"Expert Rev Clin Immunol."},{"key":"B202","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.ajpath.2010.11.065","article-title":"M2 polarized macrophages and giant cells contribute to myofibrosis in neuromuscular sarcoidosis.","volume":"178","author":"Prokop","year":"2011","journal-title":"Am J Pathol."},{"key":"B203","first-page":"120","article-title":"Th1 and Th2 responses regulate experimental lung granuloma development.","volume":"13","author":"Kunkel","year":"1996","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"key":"B204","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.it.2020.01.007","article-title":"Sarcoidosis and the mTOR, Rac1, and autophagy triad.","volume":"41","author":"Pacheco","year":"2020","journal-title":"Trends Immunol."},{"key":"B205","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/ni.3655","article-title":"Chronic signaling via the metabolic checkpoint kinase mTORC1 induces macrophage granuloma formation and marks sarcoidosis progression.","volume":"18","author":"Linke","year":"2017","journal-title":"Nat Immunol."},{"key":"B206","doi-asserted-by":"publisher","first-page":"497","DOI":"10.2353\/ajpath.2009.080580","article-title":"FoxP3+ regulatory T cells suppress early stages of granuloma formation but have little impact on sarcoidosis lesions.","volume":"174","author":"Taflin","year":"2009","journal-title":"Am J Pathol."},{"key":"B207","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1084\/jem.20050648","article-title":"The immune paradox of sarcoidosis and regulatory T cells.","volume":"203","author":"Miyara","year":"2006","journal-title":"J Exp Med."},{"key":"B208","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.clim.2011.03.015","article-title":"Regulatory T cells with reduced repressor capacities are extensively amplified in pulmonary sarcoid lesions and sustain granuloma formation.","volume":"140","author":"Rappl","year":"2011","journal-title":"Clin Immunol."},{"key":"B209","doi-asserted-by":"publisher","first-page":"5446","DOI":"10.4049\/jimmunol.1202891","article-title":"Reversal of global CD4+ subset dysfunction is associated with spontaneous clinical resolution of pulmonary sarcoidosis.","volume":"190","author":"Oswald-Richter","year":"2013","journal-title":"J Immunol."},{"key":"B210","year":"1997","journal-title":"<ext-link ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\">ClinicalTrials.gov<\/ext-link>."},{"key":"B211","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.chest.2021.05.031","article-title":"A pilot randomized trial of transdermal nicotine for pulmonary sarcoidosis.","volume":"160","author":"Crouser","year":"2021","journal-title":"Chest."},{"key":"B212","year":"2022","journal-title":"Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis."},{"key":"B213","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S2213-2600(13)70276-5","article-title":"An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study.","volume":"2","author":"Walsh","year":"2014","journal-title":"Lancet Respir Med."},{"key":"B214","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1378\/chest.06-2822","article-title":"Six-minute walk test and health status assessment in sarcoidosis.","volume":"132","author":"Baughman","year":"2007","journal-title":"Chest."},{"key":"B215","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1164\/ajrccm\/145.2_Pt_1.467","article-title":"A factor analysis of dyspnea ratings, respiratory muscle strength, and lung function in patients with chronic obstructive pulmonary disease.","author":"Mahler","year":"1992","journal-title":"Am Rev Respir Dis."},{"key":"B216","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3109\/00365513.2010.506555","article-title":"The association between interleukin-18 and pulmonary sarcoidosis: a meta-analysis.","volume":"70","author":"Liu","year":"2010","journal-title":"Scand J Clin Lab Invest."},{"key":"B217","doi-asserted-by":"publisher","first-page":"593","DOI":"10.3109\/00365513.2011.597871","article-title":"Can circulating interleukin-18 differentiate between sarcoidosis and idiopathic pulmonary fibrosis?","volume":"71","author":"Liu","year":"2011","journal-title":"Scand J Clin Lab Invest."},{"key":"B218","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1089\/jir.2006.26.400","article-title":"Upregulation of Th1 cytokine profile (IL-12, IL-18) in bronchoalveolar lavage fluid in patients with pulmonary sarcoidosis.","volume":"26","author":"Antoniou","year":"2006","journal-title":"J Interferon Cytokine Res."},{"key":"B219","doi-asserted-by":"publisher","first-page":"4718","DOI":"10.4049\/jimmunol.165.8.4718","article-title":"Role of IL-18 in CD4+ T lymphocyte activation in sarcoidosis.","volume":"165","author":"Greene","year":"2000","journal-title":"J Immunol."},{"key":"B220","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.4049\/jimmunol.161.7.3400","article-title":"IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production.","volume":"161","author":"Yoshimoto","year":"1998","journal-title":"J Immunol."},{"key":"B221","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S0952-7915(98)80163-5","article-title":"Regulation of interferon-gamma production by IL-12 and IL-18.","volume":"10","author":"Okamura","year":"1998","journal-title":"Curr Opin Immunol."},{"key":"B222","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.4049\/jimmunol.160.8.3642","article-title":"IL-12 and IL-18 differentially regulate the transcriptional activity of the human IFN-gamma promoter in primary CD4+ T lymphocytes.","volume":"160","author":"Barbulescu","year":"1998","journal-title":"J Immunol."},{"key":"B223","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1034\/j.1399-0039.2002.600105.x","article-title":"Association of single nucleotide polymorphisms in the IL-18 gene with sarcoidosis in a Japanese population.","volume":"60","author":"Takada","year":"2002","journal-title":"Tissue Antigens."},{"key":"B224","year":"2022","journal-title":"A Study to Assess the Efficacy and Safety of Namilumab in Participants with Chronic Pulmonary Sarcoidosis (RESOLVE-Lung)."},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1267-3","article-title":"Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis.","volume":"19","author":"Huizinga","year":"2017","journal-title":"Arthritis Res Ther."},{"key":"B226","doi-asserted-by":"publisher","first-page":"507","DOI":"10.5414\/CP203235","article-title":"Randomized, double-blind, placebo-controlled, phase I study of the safety and pharmacokinetics of namilumab in healthy Japanese and Caucasian men.","volume":"56","author":"Tanaka","year":"2018","journal-title":"Int J Clin Pharmacol Ther."},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-019-0231-9","article-title":"Namilumab improves RA symptoms.","volume":"15","author":"Onuora","year":"2019","journal-title":"Nat Rev Rheumatol."},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1879-x","article-title":"Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial.","volume":"21","author":"Taylor","year":"2019","journal-title":"Arthritis Res Ther."},{"key":"B229","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1111\/bjd.17195","article-title":"Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody.","volume":"180","author":"Papp","year":"2019","journal-title":"Br J Dermatol."},{"key":"B230","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1101\/2021.06.02.21258204","article-title":"Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial.","volume":"10","author":"Fisher","year":"2022","journal-title":"Lancet Respir Med."},{"key":"B231","first-page":"139","article-title":"Increased expression of tumor necrosis factor-alpha, interleukin-6, platelet-derived growth factor-B and granulocyte-macrophage colony-stimulating factor mRNA in cells of bronchoalveolar lavage fluids from patients with sarcoidosis.","volume":"13","author":"Ishioka","year":"1996","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.752856","article-title":"The role of GM-CSF autoantibodies in infection and autoimmune pulmonary alveolar proteinosis: a concise review.","volume":"12","author":"Ataya","year":"2021","journal-title":"Front Immunol."},{"key":"B233","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.coi.2009.09.004","article-title":"Pulmonary alveolar proteinosis, a primary immunodeficiency of impaired GM-CSF stimulation of macrophages.","volume":"21","author":"Trapnell","year":"2009","journal-title":"Curr Opin Immunol."},{"key":"B234","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMoa062505","article-title":"GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis.","volume":"356","author":"Uchida","year":"2007","journal-title":"N Engl J Med."},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01546-x","article-title":"Clinical significance of serum anti-granulocyte-macrophage colony-stimulating factor autoantibodies in patients with sarcoidosis and hypersensitivity pneumonitis.","volume":"15","author":"Katayama","year":"2020","journal-title":"Orphanet J Rare Dis."},{"key":"B236","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1620\/tjem.243.77","article-title":"Elevated serum anti-GM-CSF antibodies before the onset of autoimmune pulmonary alveolar proteinosis in a patient with sarcoidosis and systemic sclerosis.","volume":"243","author":"Yamasue","year":"2017","journal-title":"Tohoku J Exp Med."},{"key":"B237","year":"2022","journal-title":"Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis."},{"key":"B238","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1136\/thoraxjnl-2012-201962","article-title":"The development and validation of the King\u2019s sarcoidosis questionnaire for the assessment of health status.","volume":"68","author":"Patel","year":"2013","journal-title":"Thorax."},{"key":"B239","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1164\/ajrccm-conference.2020.201.1_MeetingAbstracts.A1537","article-title":"Evaluating the minimal clinically important difference of the King\u2019s sarcoidosis questionnaire in a multicenter prospective study.","volume":"18","author":"Baughman","year":"2021","journal-title":"Ann Am Thorac Soc."},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01228","article-title":"Multifaceted role of neuropilins in the immune system: potential targets for immunotherapy.","volume":"8","author":"Roy","year":"2017","journal-title":"Front Immunol."},{"key":"B241","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.molimm.2017.08.010","article-title":"Role of neuropilin-2 in the immune system.","volume":"90","author":"Schellenburg","year":"2017","journal-title":"Mol Immunol."},{"key":"B242","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.575","article-title":"Neuropilin-2 regulates airway inflammation in a neutrophilic asthma model.","volume":"10","author":"Immormino","year":"2022","journal-title":"Immun Inflamm Dis."},{"key":"B243","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-69281-8","article-title":"Novel protein pathways in development and progression of pulmonary sarcoidosis.","volume":"10","author":"Bhargava","year":"2020","journal-title":"Sci Rep."},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2021.OA3986","article-title":"Immunomodulatory protein ATYR1923 disrupts an in vitro model of sarcoid granuloma formation.","volume":"58","author":"Paz","year":"2021","journal-title":"Eur Respir J."},{"key":"B245","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1515\/BC.1999.079","article-title":"Histidyl-tRNA synthetase.","volume":"380","author":"Freist","year":"1999","journal-title":"Biol Chem."},{"key":"B246","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jaut.2004.01.004","article-title":"Intracellular localization of histidyl-tRNA synthetase\/Jo-1 antigen in T24 cells and some other cells.","volume":"22","author":"Kamei","year":"2004","journal-title":"J Autoimmun."},{"key":"B247","doi-asserted-by":"publisher","first-page":"5871","DOI":"10.1021\/bi00392a044","article-title":"Purification of mammalian histidyl-tRNA synthetase and its interaction with myositis-specific anti-Jo-1 antibodies.","volume":"26","author":"Fahoum","year":"1987","journal-title":"Biochemistry."},{"key":"B248","year":"2020","journal-title":"Effectiveness of Methotrexate Versus Prednisolone as First-line Therapy for Pulmonary Sarcoidosis (PREDMETH)."},{"key":"B249","year":"2022","journal-title":"A Randomized Controlled Trial of Hydroxychloroquine Combined with Low-dose Corticosteroid in Pulmonary Sarcoidosis (QUIDOSE)."},{"key":"B250","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1164\/ajrccm.160.1.9809024","article-title":"Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis.","volume":"160","author":"Baltzan","year":"1999","journal-title":"Am J Respir Crit Care Med."},{"key":"B251","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.revmed.2022.04.030","article-title":"[Hydroxychloroquine for non-severe extra-pulmonary sarcoidosis].","volume":"43","author":"Jamilloux","year":"2022","journal-title":"Rev Med Interne."},{"key":"B252","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1001\/archneur.55.9.1248","article-title":"Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement.","volume":"55","author":"Sharma","year":"1998","journal-title":"Arch Neurol."},{"key":"B253","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.clindermatol.2007.03.011","article-title":"Evidence-based therapy for cutaneous sarcoidosis.","volume":"25","author":"Baughman","year":"2007","journal-title":"Clin Dermatol."},{"key":"B254","first-page":"113","article-title":"Calcium and vitamin D metabolism in sarcoidosis.","volume":"30","author":"Baughman","year":"2013","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"key":"B255","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.545413","article-title":"Treatment of sarcoidosis: a multidisciplinary approach.","volume":"11","author":"Gerke","year":"2020","journal-title":"Front Immunol."},{"key":"B256","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","article-title":"Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology.","volume":"16","author":"Schrezenmeier","year":"2020","journal-title":"Nat Rev Rheumatol."},{"key":"B257","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00408-020-00323-8","article-title":"Ranking self-reported gastrointestinal side effects of pharmacotherapy in sarcoidosis.","volume":"198","author":"Drent","year":"2020","journal-title":"Lung."},{"key":"B258","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","article-title":"Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision).","volume":"123","author":"Marmor","year":"2016","journal-title":"Ophthalmology."},{"key":"B259","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1001\/jamaophthalmol.2014.3459","article-title":"The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy.","volume":"132","author":"Melles","year":"2014","journal-title":"JAMA Ophthalmol."},{"key":"B260","year":"2022","journal-title":"Efficacy and Safety of Two Glucocorticoid Regimens in the Treatment of Sarcoidosis (SARCORT) (NCT03265405)."},{"key":"B261","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1164\/rccm.200211-1343OC","article-title":"The sarcoidosis health questionnaire: a new measure of health-related quality of life.","volume":"168","author":"Cox","year":"2003","journal-title":"Am J Respir Crit Care Med."},{"key":"B262","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1378\/chest.125.3.997","article-title":"Health-related quality of life of persons with sarcoidosis.","volume":"125","author":"Cox","year":"2004","journal-title":"Chest."},{"key":"B263","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2020.100669","article-title":"Design, rationale, and baseline characteristics of a pilot randomized clinical trial of nicotine treatment for pulmonary sarcoidosis.","volume":"20","author":"Hade","year":"2020","journal-title":"Contemp Clin Trials Commun."},{"key":"B264","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1136\/thx.43.7.516","article-title":"Smoking and pulmonary sarcoidosis: effect of cigarette smoking on prevalence, clinical manifestations, alveolitis, and evolution of the disease.","volume":"43","author":"Valeyre","year":"1988","journal-title":"Thorax."},{"key":"B265","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/j.1749-6632.1986.tb18539.x","article-title":"Reduced prevalence of smokers in sarcoidosis. Results of a case-control study.","volume":"465","author":"Harf","year":"1986","journal-title":"Ann N Y Acad Sci."},{"key":"B266","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1164\/rccm.200402-249OC","article-title":"A case control etiologic study of sarcoidosis: environmental and occupational risk factors.","volume":"170","author":"Newman","year":"2004","journal-title":"Am J Respir Crit Care Med."},{"key":"B267","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1164\/rccm.200909-1338OC","article-title":"Smoking, use of moist snuff, and risk of chronic inflammatory diseases.","volume":"181","author":"Carlens","year":"2010","journal-title":"Am J Respir Crit Care Med."},{"key":"B268","doi-asserted-by":"publisher","first-page":"567","DOI":"10.2119\/2008-00079.Parrish","article-title":"Modulation of TNF release by choline requires alpha7 subunit nicotinic acetylcholine receptor-mediated signaling.","volume":"14","author":"Parrish","year":"2008","journal-title":"Mol Med."},{"key":"B269","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/nature01339","article-title":"Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation.","volume":"421","author":"Wang","year":"2003","journal-title":"Nature."},{"key":"B270","doi-asserted-by":"publisher","first-page":"6681","DOI":"10.4049\/jimmunol.0902212","article-title":"Activation of the cholinergic anti-inflammatory system by nicotine attenuates neuroinflammation via suppression of Th1 and Th17 responses.","volume":"183","author":"Nizri","year":"2009","journal-title":"J Immunol."},{"key":"B271","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S0306-4530(97)00076-0","article-title":"Effect of nicotine on the immune system: possible regulation of immune responses by central and peripheral mechanisms.","volume":"23","author":"Sopori","year":"1998","journal-title":"Psychoneuroendocrinology."},{"key":"B272","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brainres.2008.11.053","article-title":"Convergence of alpha 7 nicotinic acetylcholine receptor-activated pathways for anti-apoptosis and anti-inflammation: central role for JAK2 activation of STAT3 and NF-kappaB.","volume":"1256","author":"Marrero","year":"2009","journal-title":"Brain Res."},{"key":"B273","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00296-010-1549-4","article-title":"Nicotine inhibits tumor necrosis factor-alpha induced IL-6 and IL-8 secretion in fibroblast-like synoviocytes from patients with rheumatoid arthritis.","volume":"32","author":"Zhou","year":"2012","journal-title":"Rheumatol Int."},{"key":"B274","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1124\/jpet.110.169961","article-title":"Stimulation of alpha7 nicotinic acetylcholine receptor by nicotine increases suppressive capacity of naturally occurring CD4+CD25+ regulatory T cells in mice in vitro.","volume":"335","author":"Wang","year":"2010","journal-title":"J Pharmacol Exp Ther."},{"key":"B275","doi-asserted-by":"publisher","first-page":"6518","DOI":"10.4049\/jimmunol.167.11.6518","article-title":"Involvement of nicotinic acetylcholine receptors in suppression of antimicrobial activity and cytokine responses of alveolar macrophages to Legionella pneumophila infection by nicotine.","volume":"167","author":"Matsunaga","year":"2001","journal-title":"J Immunol."},{"key":"B276","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1378\/chest.12-0383","article-title":"Nicotine treatment improves Toll-like receptor 2 and Toll-like receptor 9 responsiveness in active pulmonary sarcoidosis.","volume":"143","author":"Julian","year":"2013","journal-title":"Chest."},{"key":"B277","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1136\/bmj.1.4656.745","article-title":"Sarcoidosis, with special reference to lung changes.","volume":"1","author":"Scadding","year":"1950","journal-title":"Br Med J."},{"key":"B278","first-page":"201","article-title":"Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis.","volume":"30","author":"Drake","year":"2013","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"key":"B279","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1001\/jamadermatol.2013.4646","article-title":"Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study.","volume":"149","author":"Drake","year":"2013","journal-title":"JAMA Dermatol."},{"key":"B280","doi-asserted-by":"publisher","first-page":"00534","DOI":"10.1183\/23120541.00534-2020","article-title":"Azithromycin for sarcoidosis cough: an open-label exploratory clinical trial.","volume":"6","author":"Fraser","year":"2020","journal-title":"ERJ Open Res."},{"key":"B281","year":"2016","journal-title":"Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis."},{"key":"B282","year":"2022","journal-title":"Acthar Gel in Participants With Pulmonary Sarcoidosis (PULSAR)."},{"key":"B283","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s41030-022-00181-0","article-title":"Repository corticotropin injection for the treatment of pulmonary sarcoidosis: a narrative review.","volume":"8","author":"Mirsaeidi","year":"2022","journal-title":"Pulm Ther."},{"key":"B284","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.rmed.2015.11.007","article-title":"A retrospective pilot study examining the use of acthar gel in sarcoidosis patients.","volume":"110","author":"Baughman","year":"2016","journal-title":"Respir Med."},{"key":"B285","first-page":"86","article-title":"A composite score to assess treatment response in pulmonary sarcoidosis: the sarcoidosis treatment score (STS).","volume":"36","author":"Baughman","year":"2019","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"key":"B286","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0147-2019","article-title":"Management of repository corticotrophin injection therapy for pulmonary sarcoidosis: a Delphi study.","volume":"29","author":"Rahaghi","year":"2020","journal-title":"Eur Respir Rev."},{"key":"B287","year":"2022","journal-title":"Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis."},{"key":"B288","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s12272-015-0569-8","article-title":"IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future.","volume":"38","author":"Kim","year":"2015","journal-title":"Arch Pharm Res."},{"key":"B289","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.2147\/DDDT.S100302","article-title":"Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.","volume":"11","author":"Raimondo","year":"2017","journal-title":"Drug Des Devel Ther."},{"key":"B290","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00393-017-0292-6","article-title":"Comparative efficacy and tolerability of sarilumab 150 and 200 mg in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.","volume":"77","author":"Bae","year":"2018","journal-title":"Z Rheumatol."},{"key":"B291","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.clim.2008.08.018","article-title":"The effects of IL-6 on CD4 T cell responses.","volume":"130","author":"Dienz","year":"2009","journal-title":"Clin Immunol."},{"key":"B292","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1378\/chest.106.1.156","article-title":"Significance of interleukin 6 in patients with sarcoidosis.","volume":"106","author":"Sahashi","year":"1994","journal-title":"Chest."},{"key":"B293","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1046\/j.1365-2249.1997.d01-905.x","article-title":"Increased IL-6 and IL-8 in bronchoalveolar lavage fluids (BALF) from patients with sarcoidosis: correlation with the clinical parameters.","volume":"107","author":"Takizawa","year":"1997","journal-title":"Clin Exp Immunol."},{"key":"B294","article-title":"TNF-\u03b1, IL-8, IL-6 levels in serum of sarcoidosis patients with different clinical course.","volume":"42","author":"Denisova","year":"2013","journal-title":"Eur Respir J."},{"key":"B295","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1111\/ene.13975","article-title":"The cerebrospinal fluid CD4\/CD8 ratio and interleukin-6 and -10 levels in neurosarcoidosis: a multicenter, pragmatic, comparative study.","volume":"26","author":"Chazal","year":"2019","journal-title":"Eur J Neurol."},{"key":"B296","doi-asserted-by":"publisher","first-page":"996","DOI":"10.3899\/jrheum.181089","article-title":"Endorsement of the 66\/68 joint count for the measurement of musculoskeletal disease activity: OMERACT 2018 psoriatic arthritis workshop report.","volume":"46","author":"Duarte-Garcia","year":"2019","journal-title":"J Rheumatol."},{"key":"B297","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jpainsymman.2012.02.016","article-title":"Armodafinil for sarcoidosis-associated fatigue: a double-blind, placebo-controlled, crossover trial.","volume":"45","author":"Lower","year":"2013","journal-title":"J Pain Symptom Manag."},{"key":"B298","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1378\/chest.07-2952","article-title":"Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue.","volume":"133","author":"Lower","year":"2008","journal-title":"Chest."},{"key":"B299","doi-asserted-by":"publisher","first-page":"i27","DOI":"10.1093\/rheumatology\/key256","article-title":"Clinical efficacy of new JAK inhibitors under development. Just more of the same?","author":"Westhovens","year":"2019","journal-title":"Rheumatology (Oxford)."},{"key":"B300","first-page":"187","article-title":"The promise of JAK inhibitors for treatment of sarcoidosis and other inflammatory disorders with macrophage activation: a review of the literature.","volume":"93","author":"Wang","year":"2020","journal-title":"Yale J Biol Med."},{"key":"B301","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2147\/TCRM.S192922","article-title":"Refractory sarcoidosis: a review.","volume":"16","author":"El Jammal","year":"2020","journal-title":"Ther Clin Risk Manag."},{"key":"B302","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1056\/NEJMoa1805958","article-title":"Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis.","volume":"379","author":"Damsky","year":"2018","journal-title":"N Engl J Med."},{"key":"B303","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01482-2018","article-title":"Dramatic response of refractory sarcoidosis under ruxolitinib in a patient with associated JAK2-mutated polycythemia.","volume":"52","author":"Rotenberg","year":"2018","journal-title":"Eur Respir J."},{"key":"B304","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3109\/09273941003797934","article-title":"The expression of STAT-1 and phosphorylated STAT-1 in conjunctival granulomas.","volume":"18","author":"Rosenbaum","year":"2010","journal-title":"Ocul Immunol Inflamm."},{"key":"B305","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30615-x","article-title":"Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis.","volume":"13","author":"Damsky","year":"2022","journal-title":"Nat Commun."},{"key":"B306","year":"2022","journal-title":"Efficacy of Remission-induction Regimen With Infliximab for Severe Extrathoracic Sarcoidosis (EFIRTES) (EFIRTES) (NCT03704610)."},{"key":"B307","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.rmed.2019.09.001","article-title":"Mortality for sarcoidosis patients on the transplant wait list in the lung allocation score era: experience from a high volume center.","volume":"157","author":"Gangemi","year":"2019","journal-title":"Respir Med."},{"key":"B308","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1513\/AnnalsATS.201303-069FR","article-title":"Pulmonary fibrosis in sarcoidosis. Clinical features and outcomes.","volume":"10","author":"Patterson","year":"2013","journal-title":"Ann Am Thorac Soc."},{"key":"B309","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1097\/PAS.0b013e3182785a2d","article-title":"End-stage sarcoid lung disease is distinct from usual interstitial pneumonia.","volume":"37","author":"Xu","year":"2013","journal-title":"Am J Surg Pathol."},{"key":"B310","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.rmed.2012.11.011","article-title":"Severity of pulmonary involvement and (18)F-FDG PET activity in sarcoidosis.","volume":"107","author":"Mostard","year":"2013","journal-title":"Respir Med."},{"key":"B311","doi-asserted-by":"publisher","DOI":"10.3390\/cells11040664","article-title":"Comparative analysis of gene expression in fibroblastic foci in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis.","volume":"11","author":"Kamp","year":"2022","journal-title":"Cells."},{"key":"B312","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1097\/00007691-199512000-00023","article-title":"Mechanism of action of mycophenolate mofetil.","volume":"17","author":"Ransom","year":"1995","journal-title":"Ther Drug Monit."},{"key":"B313","doi-asserted-by":"publisher","first-page":"s2","DOI":"10.1177\/096120330501400102","article-title":"Mechanisms of action of mycophenolate mofetil.","author":"Allison","year":"2005","journal-title":"Lupus."},{"key":"B314","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1002\/art.40114","article-title":"Mycophenolate mofetil versus placebo for systemic sclerosis-related interstitial lung disease: an analysis of scleroderma lung studies I and II.","volume":"69","author":"Volkmann","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"B315","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med."},{"key":"B316","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease.","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med."},{"key":"B317","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/MCP.0b013e3283486d52","article-title":"Sarcoidosis and interstitial pulmonary fibrosis; two distinct disorders or two ends of the same spectrum.","volume":"17","author":"Shigemitsu","year":"2011","journal-title":"Curr Opin Pulm Med."},{"key":"B318","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1378\/chest.15-0615","article-title":"Histopathology of explanted lungs from patients with a diagnosis of pulmonary sarcoidosis.","volume":"149","author":"Zhang","year":"2016","journal-title":"Chest."},{"key":"B319","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases.","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med."},{"key":"B320","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline.","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med."},{"key":"B321","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1513\/AnnalsATS.202103-343OC","article-title":"Nintedanib in progressive pulmonary fibrosis: a systematic review and meta-analysis.","volume":"19","author":"Ghazipura","year":"2022","journal-title":"Ann Am Thorac Soc."},{"key":"B322","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","article-title":"Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.","volume":"8","author":"Wells","year":"2020","journal-title":"Lancet Respir Med."},{"key":"B323","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.2214\/ajr.174.6.1741751","article-title":"Sarcoidosis with pulmonary fibrosis: CT patterns and correlation with pulmonary function.","volume":"174","author":"Abehsera","year":"2000","journal-title":"AJR Am J Roentgenol."},{"key":"B324","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1016\/j.rmed.2013.10.014","article-title":"Frequency of acute worsening events in fibrotic pulmonary sarcoidosis patients.","volume":"107","author":"Baughman","year":"2013","journal-title":"Respir Med."},{"key":"B325","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MAJ.0b013e3181b97635","article-title":"Efficacy of short-course, low-dose corticosteroid therapy for acute pulmonary sarcoidosis exacerbations.","volume":"339","author":"McKinzie","year":"2010","journal-title":"Am J Med Sci."},{"key":"B326","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1007\/s12325-021-02014-z","article-title":"Using data on survival with idiopathic pulmonary fibrosis to estimate survival with other types of progressive fibrosis interstitial lung disease: a bayesian framework.","volume":"39","author":"Langford","year":"2022","journal-title":"Adv Ther."},{"key":"B327","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1056\/NEJMoa1103690","article-title":"Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.","volume":"365","author":"Richeldi","year":"2011","journal-title":"N Engl J Med."},{"key":"B328","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-85234-1","article-title":"Initial therapeutic dose of corticosteroid for an acute exacerbation of IPF is associated with subsequent early recurrence of another exacerbation.","volume":"11","author":"Yamazaki","year":"2021","journal-title":"Sci Rep."},{"key":"B329","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/resp.13753","article-title":"Corticosteroid use is not associated with improved outcomes in acute exacerbation of IPF.","volume":"25","author":"Farrand","year":"2020","journal-title":"Respirology."},{"key":"B330","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-016-0298-x","article-title":"Acute exacerbation of IPF has systemic consequences with multiple organ injury, with SRA(+) and TNF-alpha(+) cells in the systemic circulation playing central roles in multiple organ injury.","volume":"16","author":"Emura","year":"2016","journal-title":"BMC Pulm Med."},{"key":"B331","year":"2022","journal-title":"A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis (RESOLVE-Heart)."},{"key":"B332","year":"2019","journal-title":"Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis (MAGiC-ART)."},{"key":"B333","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-021-03130-8","article-title":"Interleukin-1 blockade in cardiac sarcoidosis: study design of the multimodality assessment of granulomas in cardiac sarcoidosis: anakinra randomized trial (MAGiC-ART).","volume":"19","author":"Kron","year":"2021","journal-title":"J Transl Med."},{"key":"B334","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1016\/j.jacc.2017.09.028","article-title":"Interleukin-1 beta as a target for atherosclerosis therapy: biological basis of CANTOS and beyond.","volume":"70","author":"Libby","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"B335","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1093\/eurheartj\/ehy128","article-title":"Interleukin-1 blockade in cardiovascular diseases: a clinical update.","volume":"39","author":"Buckley","year":"2018","journal-title":"Eur Heart J."},{"key":"B336","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.119.007582","article-title":"Inflammasome formation in granulomas in cardiac sarcoidosis.","volume":"12","author":"Kron","year":"2019","journal-title":"Circ Arrhythm Electrophysiol."},{"key":"B337","doi-asserted-by":"publisher","first-page":"i2","DOI":"10.1136\/ard.2009.123885","article-title":"Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009.","volume":"69","author":"Furst","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"B338","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.amjcard.2014.11.003","article-title":"Comparative safety of interleukin-1 blockade with anakinra in patients with ST-segment elevation acute myocardial infarction (from the VCU-ART and VCU-ART2 pilot studies).","volume":"115","author":"Abbate","year":"2015","journal-title":"Am J Cardiol."},{"key":"B339","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.004373","article-title":"Interleukin-1 blockade in recently decompensated systolic heart failure: results from REDHART (recently decompensated heart failure anakinra response trial).","volume":"10","author":"Van Tassell","year":"2017","journal-title":"Circ Heart Fail."},{"key":"B340","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033438","article-title":"Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure.","volume":"7","author":"Van Tassell","year":"2012","journal-title":"PLoS One."},{"key":"B341","year":"2018","journal-title":"Cardiac Sarcoidosis Randomized Trial (CHASM-CS-RCT)."},{"key":"B342","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.ijcard.2018.11.131","article-title":"Treatment of cardiac sarcoidosis: a comparative study of steroids and steroids plus immunosuppressive drugs.","volume":"276","author":"Ballul","year":"2019","journal-title":"Int J Cardiol."},{"key":"B343","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.53.3120","article-title":"Treatment with methotrexate and low-dose corticosteroids in sarcoidosis patients with cardiac lesions.","volume":"53","author":"Nagai","year":"2014","journal-title":"Intern Med."},{"key":"B344","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1002\/joa3.12084","article-title":"Japanese antibacterial drug management for cardiac sarcoidosis (J-ACNES): a multicenter, open-label, randomized, controlled study.","volume":"34","author":"Ishibashi","year":"2018","journal-title":"J Arrhythm."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.991783\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T23:13:53Z","timestamp":1678230833000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.991783\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,12]]},"references-count":344,"alternative-id":["10.3389\/fmed.2022.991783"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.991783","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,12]]},"article-number":"991783"}}